If a patient's adaptive immune system produces antibodies that bind to and block the PD-1 receptor on T-cells, which consequence follows regarding immune responses to cancer cells?

💡 Explanation

Blocking PD-1 with antibodies prevents its interaction with PD-L1 on cancer cells. This interaction normally inhibits T-cell activation; therefore, blocking PD-1 unleashes T-cell mediated cytotoxicity against cancer cells, rather than diminishing it. Cancer cell MHC-I expression or antigen presentation efficiency are not directly affected by this mechanism.

• Why does the perceived color of an object under low-light conditions shift towards blues and greens, even if the object is normally red?
• Why does the liver utilize both glycolysis and gluconeogenesis pathways despite their opposing functions?
• Why does neuronal damage continue in some neurodegenerative diseases even after the initial triggering event?
• Which consequence occurs in prolonged Granulocyte Colony-Stimulating Factor (G-CSF) treatment?
• A patient with severe mitral valve stenosis experiences increased left atrial pressure. Which outcome is most likely in the pulmonary circulation due to this cardiac condition?
• Why does a hydrophilic drug, like gentamicin, typically exhibit a smaller volume of distribution compared to a lipophilic drug, such as diazepam?